People

The strength of I²D³ lies in the people behind it. Our community brings together leading scientists in pharmacokinetics, peptide design, and antibody engineering, alongside collaborators in biotech, data science, and clinical practice. Together, we’re building the expertise and partnerships needed to transform drug development from the inside out.

Leadership

Guarav Bhardwaj

PhD – Co-Director, Peptide Design

Leader in computational peptide design andAI-enabled drug delivery.

Nina Isoherranen

PhD – Co-Director, PBPK Modeling

Internationally recognized expert in drug metabolism and translational PK; integrates ML into predictive PBPK modeling.

Marco Pravetoni

PhD – Co-Director, Antibody Engineering

Pioneer in immunotherapeutics and drug-delivery platforms.

Member Labs

Jay Panyam

Jay Panyam

Description Test

Rheem Totah

Rheem Totah

Description Test

Abhi Nath

Abhi Nath

Description test

David Baker

David Baker

Description test

Scientific Advisors

Vishva Dixit — Physiological Chemistry, Genentech
John Karanicolas — Head of Computational Drug Discovery, AbbVie
Neil McDonnell — CEO, Seal Rock Therapeutics
Brooke Rock — ED, Pharmacokinetics and Drug Metabolism, Amgen
Josh Pearson — Vice President, head of PDMB, Merck Research Labs
Peter Senter — Retired, Pfizer / Seattle Genetics
Matt Thomlinson — Chief Technology Officer, Electronic Arts

AI designed protein structures from the Baker Lab